– USA, PA – Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced the appointment of Dr. Michael Kamarck (Ph.D.) to its board of directors.
“We are thrilled to welcome Michael to our board as we continue to advance our clinical programs in our mission to bring transformative therapies to patients with CNS disorders. His wealth of experience in manufacturing and technical operations, critical areas for a genetic medicines company, will provide valuable guidance as we continue to build on the strong technical foundation we have established,” said Dr. Maxine Gowen, interim executive chairwoman.
He will also join the Nominating and Corporate Governance Committee.
About Dr. Michael Kamarck
Dr. Michael Kamarck is a seasoned biopharmaceutical executive with over forty years of experience in discovery research, process development, and technical operations.
Dr. Kamarck is the Chairman of the Sanofi Biotech Advisory Council, providing strategic guidance to advance Sanofi’s biological business. He recently retired as CTO for Vir Biotechnology, Inc., where he led a multi-modality technical approach to the development of treatments for serious infectious diseases such as COVID-19 (sotrovimab), influenza, and hepatitis B. Before joining Vir, Dr. Kamarck was SVP of Global Vaccines and Biologics Manufacturing and President of Merck BioVentures. In this role, he was responsible for the worldwide manufacturing network in support of the vaccine portfolio and biologics businesses. Dr. Kamarck also held numerous senior executive positions at Wyeth Pharmaceuticals, including President, Technical Operations, and Product Supply as a member of the Wyeth Management Team. While with Wyeth, he was responsible for establishing a global biotechnology network of more than 10,000 employees to develop and manufacture numerous blockbuster products, including building the manufacturing infrastructure to deliver the global supply of Prevnar 13® and Enbrel®. Dr. Kamarck also spent 16 years at Bayer AG serving in numerous roles, including SVP of Operations for Bayer Biologicals. He has authored more than 50 peer-reviewed publications and has 20 issued patents. He currently serves on the board of directors of Vaxcyte, Inc.
“I am thrilled to join Passage Bio’s board and Nominating and Governance Committee as the company enters an exciting phase of clinical development and continues to build on its impressive technical operations capabilities,” said Dr. Kamarck. “I look forward to partnering with the Board and management team to ensure Passage Bio remains at the leading edge of manufacturing and technical capabilities as we plan for continued clinical success, moving closer to bringing these therapies to patients with devastating CNS disorders.”
Dr. Kamarck holds a Ph.D. in biochemistry from the Massachusetts Institute of Technology and a bachelor’s degree in biology from Oberlin College.
About Passage Bio
Passage Bio is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing three clinical programs in GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia with several additional programs in preclinical development. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing, and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies.
For more information: https://www.passagebio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.